Abbott Laboratories $ABT Shares Purchased by VELA Investment Management LLC

Posted by Brian Himes on Sep 8th, 2026

VELA Investment Management LLC raised its stake in shares of Abbott Laboratories (NYSE:ABT – Free Report) by 164.1% in the second quarter, according to its most recent 13F filing with the SEC. The fund owned 54,892 shares of the healthcare product maker’s stock after buying an additional 34,106 shares during the period. Abbott Laboratories comprises about 1.1% of VELA Investment Management LLC’s portfolio, making the stock its 23rd largest holding. VELA Investment Management LLC’s holdings in Abbott Laboratories were worth $4,981,000 as of its most recent filing with the SEC.

A number of other hedge funds have also recently modified their holdings of ABT. Corient Private Wealth LP grew its holdings in Abbott Laboratories by 9.1% during the second quarter. Corient Private Wealth LP now owns 1,818,488 shares of the healthcare product maker’s stock worth $165,010,000 after acquiring an additional 151,301 shares during the period. Tucker Asset Management LLC lifted its holdings in Abbott Laboratories by 11.1% in the second quarter. Tucker Asset Management LLC now owns 3,467 shares of the healthcare product maker’s stock valued at $315,000 after acquiring an additional 345 shares during the period. HORAN Wealth LLC grew its stake in shares of Abbott Laboratories by 3.1% during the 2nd quarter. HORAN Wealth LLC now owns 38,698 shares of the healthcare product maker’s stock worth $3,511,000 after purchasing an additional 1,161 shares during the period. Amundi grew its stake in shares of Abbott Laboratories by 20.2% during the 2nd quarter. Amundi now owns 8,906,252 shares of the healthcare product maker’s stock worth $808,142,000 after purchasing an additional 1,499,291 shares during the period. Finally, Groupe la Francaise increased its holdings in shares of Abbott Laboratories by 22.3% during the 2nd quarter. Groupe la Francaise now owns 57,813 shares of the healthcare product maker’s stock valued at $5,248,000 after purchasing an additional 10,556 shares in the last quarter. Hedge funds and other institutional investors own 75.18% of the company’s stock.

Abbott Laboratories Stock Performance

NYSE:ABT opened at $108.29 on Tuesday. The company has a market cap of $187.38 billion, a P/E ratio of 35.05, a P/E/G ratio of 2.01 and a beta of 0.59. Abbott Laboratories has a twelve month low of $81.97 and a twelve month high of $137.49. The company’s 50-day moving average price is $104.74 and its 200-day moving average price is $100.00. The company has a current ratio of 1.38, a quick ratio of 0.97 and a debt-to-equity ratio of 0.57.

Abbott Laboratories (NYSE:ABT – Get Free Report) last issued its earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.28 by $0.03. Abbott Laboratories had a return on equity of 17.69% and a net margin of 11.65%.The business had revenue of $12.59 billion during the quarter, compared to the consensus estimate of $12.52 billion. During the same period last year, the company earned $1.26 EPS. The company’s revenue for the quarter was up 13.0% on a year-over-year basis. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. On average, sell-side analysts forecast that Abbott Laboratories will post 5.52 earnings per share for the current fiscal year.

Abbott Laboratories Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, August 17th. Stockholders of record on Wednesday, July 15th were issued a $0.63 dividend. This represents a $2.52 annualized dividend and a dividend yield of 2.3%. The ex-dividend date was Wednesday, July 15th. Abbott Laboratories’s dividend payout ratio is currently 81.55%.

Analysts Set New Price Targets

A number of research analysts have weighed in on ABT shares. UBS Group cut their price objective on shares of Abbott Laboratories from $135.00 to $125.00 and set a “buy” rating for the company in a report on Tuesday, July 28th. Wells Fargo & Company increased their target price on shares of Abbott Laboratories from $109.00 to $112.00 and gave the stock an “overweight” rating in a research note on Friday, July 17th. Robert W. Baird initiated coverage on Abbott Laboratories in a research note on Wednesday, July 1st. They issued an “outperform” rating and a $121.00 price target for the company. Royal Bank Of Canada reaffirmed an “outperform” rating and issued a $130.00 price target on shares of Abbott Laboratories in a report on Friday, July 17th. Finally, JPMorgan Chase & Co. increased their price target on Abbott Laboratories from $110.00 to $120.00 and gave the stock an “overweight” rating in a research report on Friday, July 17th. Three research analysts have rated the stock with a Strong Buy rating, twenty have given a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat, Abbott Laboratories has an average rating of “Moderate Buy” and a consensus target price of $119.50.

Check Out Our Latest Research Report on ABT

Abbott Laboratories Company Profile

(Free Report)

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.